Doctor Mike Hansen - WARNING: Do NOT Use "Compounded Ozempic" Until You Watch This

Short Summary

Main recommendation: Treat "compounded Ozempic" as three different categories (legitimate patient-specific compounding, mass-marketed unapproved copycats, and outright illegal or counterfeit products) and verify the source, active ingredient, and clinician oversight before using any of them. The video stresses that the FDA's February 6, 2026 action targets mass-marketed copies and their supply chain, not all compounding.

Key Points

• The FDA reported 605 adverse event reports tied to compounded semaglutide and 545 tied to compounded tirzepatide as of July 31, 2025, and says these numbers are likely underreported because many pharmacies are not required to submit them.
• The FDA's February 6, 2026 action restricts access to GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded drugs marketed as alternatives, and it targets false claims that these products are generic, identical in active ingredient, or clinically proven.
• The FDA has warned about dosing errors with compounded injectable semaglutide, with some people taking five to 20 times the intended dose, and some needing medical attention or hospitalization.
• Some products sold as semaglutide may use salt forms such as semaglutide sodium or semaglutide acetate, which the FDA says are different active ingredients than the base form in approved drugs, with no lawful basis known for their use in compounding.
• The FDA states it did not say all compounding is illegal, that people on compounded products are necessarily doing something wrong, or that approved drugs are risk-free.

Details Worth Noting

• Concrete instructions: Before using a compounded GLP-1 product, ask the prescriber and pharmacy these questions: What active ingredient form is used (base or salt)? Is the pharmacy state-licensed, and does the label clearly name the pharmacy and address? Is it a 503A patient-specific pharmacy or a registered 503B outsourcing facility? What is the refrigeration and shipping process, and what is the protocol if it arrives warm? What is the concentration, and how is the dose communicated to reduce confusion? What side effects are expected and what are the red flags? What is the follow-up plan if side effects or quality problems occur? Clear answers lower risk; vague answers raise it.
• Concrete instructions: Verify that the source is real. The FDA has warned about fraudulent labels naming pharmacies that do not exist or that did not actually compound the product, so a label alone is not enough.
• Concrete instructions: Confirm cold-chain handling, since injectable GLP-1 medications require refrigeration and the FDA has received complaints about products arriving warm or with inadequate ice packs.
• Concrete instructions: Prefer dosing systems that reduce error. FDA-approved injectables come in standardized pens, while many compounded products use multi-dose vials with variable concentrations, which the video links to accidental overdosing.
• Concrete instructions: Seek urgent evaluation for persistent vomiting with inability to stay hydrated, severe or worsening abdominal pain especially with repeated vomiting, signs of dehydration, fainting, severe dizziness, very low urine output, a severe allergic-type reaction (swelling, trouble breathing, widespread hives), or a rapidly worsening injection-site reaction with spreading redness, significant pain, or fever.
• The video notes that some compounders add ingredients such as vitamin B12, B6, carnitine, or NAD; the FDA says the safety and effectiveness of combining these with semaglutide have not been established.
• The video cites FDA warnings about illegal online sales and products falsely labeled "for research purposes, not for human consumption."
• The speaker frames the discussion as educational only and not medical advice, and does not address individualized dosing or treatment.

Bottom Line

Compounded Ozempic is a spectrum rather than one product: legitimate compounding is not FDA-approved and needs stronger safety checks, while mass-marketed copies and illegal online products carry substantially higher risk, and the FDA is tightening enforcement on that side.